AIM: To observe the efficacy of omeprazole combined with domperidone on functional dyspepsia ( FD ) , and provide theoretic basis for the clinical treatment of FD. METHODS: A total of 206 cases of FD patients admitted into our hospital from April 2007 to April 2013 were selected and randomly divided into observation group ( n=103 ) and control group ( n=103 ) . They were respectively given omeprazole combined with domperidone and simple application of omeprazole. The symptom score improvement, efficacy and adverse reaction of two groups before and after treatment were compared. RESULTS: The stomach burning sensation, postprandial satiety, epigastric pain, and belching symptoms score decreased significantly after treatment in the two groups, in which the observation group decreased more obviously, and the difference was statistically significant(P<0.05);the clinical total effective rate was 93. 2% in the observation group, which is significantly higher than 72. 8% in the control group, the difference was statistically significant(P<0.05); the incidence of adverse reaction was 7.8% in the observation group, while the control group was 6. 8%, and there was no statistically significant difference between the two groups ( P>0. 05 ); SDS, SAS scores after treatment were significantly reduced, the observation group reduced more obviously, and the difference was statistically significant(P<0.05); the FP of electrogastrogram, percentage of normal gastric slow wave after treatment increased significantly, the observation group incresed more obviously, and the difference was statistically significant ( P<0.05);neuropeptide Y and motilin level were increased significantly in the observation group, while the control group showed no significant change(P>0.05). CON-CLUSION:Omeprazole combined with domperidone can effectively relieve the clinical symptoms of FD patients, alleviate their psychological pressure, improve the level of gastric motility, and it won't cause serious adverse reaction. It is a safe and effective treatment for FD, which is worthy of clinical application.%目的:观察奥美拉唑联合多潘立酮对功能性消化不良的治疗效果,为功能性消化不良的临床治疗提供研究依据.方法:选取我院2007-04/2013-04收治的206例功能性消化不良患者,按照随机数字表法分为观察组( n=103)及对照组( n=103) ,分别给予奥美拉唑联合多潘立酮及单纯应用奥美拉唑治疗,比较两组患者治疗前后症状分级评分变化及其疗效、不良反应. 结果:两组患者治疗后胃部烧灼感、餐后饱胀感、上腹疼痛、嗳气症状评分均较治疗前显著降低,观察组降低程度更为显著,差异具有统计学意义(P<0.05);观察组临床总有效率为93.2%,显著高于对照组的72.8%,差异具有统计学意义( P<0.05);观察组患者不良反应发生率为7.8%,对照组为6. 8%,两组患者不良反应发生率无明显统计学差异( P>0.05);两组患者治疗后SDS、SAS评分均显著降低,观察组降低程度更为明显, 差异具有统计学意义( P<0.05);两组患者治疗后胃电图主频、胃电图正常慢波百分比显著升高,观察组升高更为显著, 差异具有统计学意义(P<0.05),治疗后观察组神经肽 Y、胃动素水平显著上升,对照组无明显变化( P>0.05) . 结论:奥美拉唑联合多潘立酮能够有效减轻功能性消化不良患者的临床症状,缓解其心理压力,改善其胃动力水平,在取得良好疗效的同时未引起严重不良反应的发生,是一种安全、有效的功能性消化不良治疗方案,值得临床推广应用.
展开▼
